Clinical Trials Logo

Brain Neoplasms clinical trials

View clinical trials related to Brain Neoplasms.

Filter by:

NCT ID: NCT05571579 Recruiting - Brain Tumor Clinical Trials

Biological Collection of Brain Tumors

GLIOLI
Start date: November 22, 2023
Phase:
Study type: Observational

The objective of this study is to build a collection of biological samples from patients with brain tumors.

NCT ID: NCT05564949 Recruiting - Cancer Clinical Trials

A Ketogenic Diet as a Complementary Treatment on Patients With High-grade Gliomas and Brain Metastases

Start date: September 20, 2022
Phase: N/A
Study type: Interventional

The survival interval of patients with gliomas ranges between 12 to 15 months. Recent findings revealed that dietary interventions to reduce glucose and glycolytic pathways could have a therapeutic effect. Ketosis can be an effective therapy to extend the survival of patients with gliomas.

NCT ID: NCT05559853 Recruiting - Brain Metastases Clinical Trials

Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment

Start date: September 22, 2022
Phase:
Study type: Observational

The purpose of this study is to develop and test a new magnetic resonance imaging (MRI) technique to see if it can be used to tell the difference between tumor growth from worsening of cancer and growth from the effects of treatment in participants who have brain tumors treated with radiation therapy called stereotactic radiosurgery (SRS).

NCT ID: NCT05554302 Recruiting - Brain Metastases Clinical Trials

Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis

CONCORDANT
Start date: January 10, 2023
Phase: Phase 2
Study type: Interventional

This study is for patients who have had surgery to remove brain metastasis and are planned to have stereotactic radiosurgery (SRS) after their brain surgery. It will be optional for patients to have a pre-surgery 18F-Fluciclovine PET/CT scan. The goal of the study is to determine whether a specific imaging agent, known as 18F-Fluciclovine, will help physicians evaluate the extent of surgery and determine if there is any visible tumor above what MRI alone can identify as well as improve the physicians' ability to detect recurring disease. This agent (18F-Fluciclovine) is investigational for the imaging of brain metastases.

NCT ID: NCT05553899 Recruiting - Clinical trials for Brain Tumor, Pediatric

Utility of PET-MRI in Surveillance of Paediatric Brain Tumours

PET-MRI
Start date: February 28, 2024
Phase: N/A
Study type: Interventional

This is a pilot project to explore the utility of PET-MRI in the post-treatment surveillance of high-grade gliomas or medulloblastomas in children in our institution.

NCT ID: NCT05553522 Recruiting - Brain Metastases Clinical Trials

Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer

Start date: January 29, 2024
Phase: Phase 1
Study type: Interventional

This research study will evaluate how well brain metastases associated with HER-2 positive breast cancer can be controlled using a type of radiation known as stereotactic radiosurgery (SRS) when combined with three therapeutic agents, tucatinib, capecitabine, and trastuzumab. The combined use of SRS with the three drugs is considered investigational.

NCT ID: NCT05549414 Recruiting - Brain Cancer Clinical Trials

Pivotal Study of Proton Radiotherapy Treatments Using Fixed Beam Chair-Based Delivery System

PPTS
Start date: March 30, 2023
Phase: N/A
Study type: Interventional

This study with Chair-Based, Gantry-less Proton System (CBGS) (aka P-CURE Proton Beam Therapy System or Fixed Beam Chair-based Delivery System) is composed of 3 arms, as following: ARM1: Patients with locally recurrent, previously irradiated thoracic cancer indicated for re- irradiation. ARM2: Patients with recurrent Head and Neck, Brain and Spinal Cord tumors, indicated for re- irradiation. ARM3: Patients with unresectable pancreatic cancer. The primary objectives of the study for all arms are: 1. to describe the efficacy (local control after 3 month) and acute toxicity for patients treated with a fully-integrated CBGS and (2) to compare treatment plans between the fully-integrated CBGS and Photon therapy defined for each patient, based upon OAR sparing for comparable target coverage.

NCT ID: NCT05549024 Recruiting - Breast Cancer Clinical Trials

68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients

Start date: August 16, 2022
Phase: Early Phase 1
Study type: Interventional

Based on the high expression of specific receptors on the surface of diseased tissues and neovascularization, noninvasive targeted molecular imaging can be used to visualize lesions in vitro by combining specific ligands labeled with short half-life isotopes. In this study, a novel dual-target imaging agent 68Ga-RM26-RGD was used for clinical study of tumor PET/CT imaging to further verify its clinical application value.

NCT ID: NCT05545007 Recruiting - Clinical trials for Brain Metastases, Adult

Preoperative vs Postoperative Hypofractionated Radiosurgery for Patients With Large Brain Metastases

SUPPORT
Start date: January 31, 2023
Phase: N/A
Study type: Interventional

This is a phase III randomized trial with the aim to compare preoperative HSRS to postoperative HSRS in patients with large at least one BMs from solid tumors suitable for surgical resection.

NCT ID: NCT05539677 Recruiting - Prostate Cancer Clinical Trials

Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research

REGATA
Start date: September 1998
Phase:
Study type: Observational [Patient Registry]

The investigators will collect biosamples of patient blood and tumour tissue for further immunological analysis of blood cell subpopulations, immunosupressive factors concentration, HLA expression an lymphocytes and tumour tissue, and and cancer testis antigenes expression on tumour cells, as well as clinical data on patient's stage, therapy, response and demographics. Possible prognostic and predictive dynamic biomarkers will be discovered for individualisation of treatment strategies